$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000114420413027413 Filed on May 09, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$3.531M	$3.833M	$4.642M
YoY Change	-50.29%	-17.43%	456.59%
Cost Of Revenue	$1.632M	$1.712M	$3.786M
YoY Change	-68.11%	-54.78%	1003.79%
Gross Profit	$1.899M	$2.121M	$856.0K
YoY Change	-4.33%	147.78%	74.34%
Gross Profit Margin	53.78%	55.34%	18.44%
Selling, General & Admin	$4.000M	$2.900M	$3.100M
YoY Change	60.0%	-6.45%	6.9%
% of Gross Profit	210.64%	136.73%	362.15%
Research & Development	$10.79M	$9.256M	$5.338M
YoY Change	100.8%	73.4%	5.27%
% of Gross Profit	567.93%	436.4%	623.6%
Depreciation & Amortization	$600.0K	$400.0K	$400.0K
YoY Change	50.0%	0.0%	0.0%
% of Gross Profit	31.6%	18.86%	46.73%
Operating Expenses	$10.79M	$9.256M	$5.338M
YoY Change	100.8%	73.4%	5.27%
Operating Profit	-$12.90M	-$10.01M	-$7.467M
YoY Change	120.29%	33.99%	0.5%
Interest Expense	$45.00K	$22.00K	$3.000K
YoY Change	1400.0%	633.33%	50.0%
% of Operating Profit
Other Income/Expense, Net			$0.00
YoY Change
Pretax Income	-$12.63M	-$9.979M	-$7.336M
YoY Change	113.31%	36.03%	-2.19%
Income Tax	$5.000K	$17.00K
% Of Pretax Income
Net Earnings	-$12.63M	-$9.996M	-$7.336M
YoY Change	113.4%	36.26%	-1.57%
Net Earnings / Revenue	-357.77%	-260.79%	-158.04%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.658M	-$1.351M	-$1.159M
COMMON SHARES
Basic Shares Outstanding	152.5M shares	147.9M
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.60M	$44.30M	$20.70M
YoY Change	53.21%	114.01%	-13.39%
Cash & Equivalents	$2.574M	$9.023M	$13.87M
Short-Term Investments	$38.00M	$35.30M	$6.800M
Other Short-Term Assets	$20.00K	$886.0K	$177.0K
YoY Change	-92.34%	400.56%	-89.59%
Inventory
Prepaid Expenses	$2.024M	$2.167M	$2.411M
Receivables	$907.0K	$2.602M	$1.725M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$45.37M	$51.72M	$26.44M
YoY Change	29.7%	95.61%	-8.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.32M	$11.62M	$7.949M
YoY Change	71.8%	46.14%	0.62%
Goodwill	$33.14M	$33.14M	$33.14M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$1.100M
YoY Change
Other Assets	$335.0K	$350.0K	$350.0K
YoY Change	-4.29%	0.0%	75.0%
Total Long-Term Assets	$47.55M	$46.98M	$42.20M
YoY Change	13.22%	11.34%	2.66%
TOTAL ASSETS
Total Short-Term Assets	$45.37M	$51.72M	$26.44M
Total Long-Term Assets	$47.55M	$46.98M	$42.20M
Total Assets	$92.92M	$98.70M	$68.64M
YoY Change	20.71%	43.81%	-2.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.946M	$2.173M	$2.959M
YoY Change	-12.84%	-26.56%	-12.97%
Accrued Expenses	$7.223M	$5.842M	$4.478M
YoY Change	28.23%	30.46%	-6.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$600.0K	$400.0K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$11.26M	$9.253M	$7.841M
YoY Change	19.47%	18.01%	-29.36%
LONG-TERM LIABILITIES
Long-Term Debt	$1.900M	$1.500M	$400.0K
YoY Change	375.0%	275.0%	33.33%
Other Long-Term Liabilities	$10.60M	$10.40M	$6.100M
YoY Change	73.77%	70.49%	17.31%
Total Long-Term Liabilities	$12.50M	$11.90M	$6.500M
YoY Change	92.31%	83.08%	18.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.26M	$9.253M	$7.841M
Total Long-Term Liabilities	$12.50M	$11.90M	$6.500M
Total Liabilities	$23.69M	$21.14M	$14.31M
YoY Change	49.03%	47.67%	-13.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$380.8M	-$368.2M	-$337.0M
YoY Change	11.05%	9.25%
Common Stock	$1.532M	$1.517M	$1.226M
YoY Change	15.54%	23.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.450M	$2.450M	$2.450M
YoY Change	0.0%	0.0%
Treasury Stock Shares	455.4K shares	455.4K shares	455.4K shares
Shareholders Equity	$69.23M	$77.57M	$54.32M
YoY Change
Total Liabilities & Shareholders Equity	$92.92M	$98.70M	$68.64M
YoY Change	20.71%	43.81%	-2.09%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$12.63M	-$9.996M	-$7.336M
YoY Change	113.4%	36.26%	-1.57%
Depreciation, Depletion And Amortization	$600.0K	$400.0K	$400.0K
YoY Change	50.0%	0.0%	0.0%
Cash From Operating Activities	-$7.600M	-$10.58M	-$4.220M
YoY Change	24.59%	150.78%	-53.32%
INVESTING ACTIVITIES
Capital Expenditures	-$1.700M	-$1.500M	-$800.0K
YoY Change	466.67%	87.5%
Acquisitions
YoY Change
Other Investing Activities	-$1.600M	-$3.400M	-$2.500M
YoY Change	-61.9%	36.0%	-131.25%
Cash From Investing Activities	-$3.200M	-$4.974M	-$3.270M
YoY Change	-28.89%	52.11%	-140.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.425M	$7.923M
YoY Change		-18.91%	501.59%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.400M	$7.181M	$7.259M
YoY Change	-63.64%	-1.07%	436.51%
NET CHANGE
Cash From Operating Activities	-7.600M	-$10.58M	-$4.220M
Cash From Investing Activities	-3.200M	-$4.974M	-$3.270M
Cash From Financing Activities	4.400M	$7.181M	$7.259M
Net Change In Cash	-6.400M	-$8.376M	-$231.0K
YoY Change	-526.67%	3525.97%	-177.78%
FREE CASH FLOW
Cash From Operating Activities	-$7.600M	-$10.58M	-$4.220M
Capital Expenditures	-$1.700M	-$1.500M	-$800.0K
Free Cash Flow	-$5.900M	-$9.083M	-$3.420M
YoY Change	1.72%	165.58%	-62.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	152464007	shares
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX INC
CY2013Q1	dei	Trading Symbol TradingSymbol	NVAX
CY2011Q4	nvax	Additional Tenant Improvement Allowance AdditionalTenantImprovementAllowance	3000000	USD
CY2008Q3	nvax	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.5
CY2008Q3	nvax	Common Shares Per Unit CommonSharesPerUnit	1
CY2013Q1	nvax	Common Stock Value Authorized Under Current Shelf Registration Statement CommonStockValueAuthorizedUnderCurrentShelfRegistrationStatement	200000000	USD
CY2012Q4	nvax	Common Stock Value Authorized Under Prior Shelf Registration Statement CommonStockValueAuthorizedUnderPriorShelfRegistrationStatement	50000000	USD
CY2012Q3	nvax	Debt Instrument Term DebtInstrumentTerm	P42M
CY2013Q1	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment		USD
CY2012Q1	nvax	Deposits For Acquisition Of Property And Equipment DepositsForAcquisitionOfPropertyAndEquipment	500000	USD
CY2013Q1	nvax	Joint Venture Percentage Owned By Others JointVenturePercentageOwnedByOthers	0.2	pure
CY2013Q1	nvax	Loan Agreement Future Minimum Payments Due LoanAgreementFutureMinimumPaymentsDue	1280000	USD
CY2013Q1	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Four LoanAgreementFutureMinimumPaymentsDueInRollingYearFour	207000	USD
CY2013Q1	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Three LoanAgreementFutureMinimumPaymentsDueInRollingYearThree	390000	USD
CY2013Q1	nvax	Loan Agreement Future Minimum Payments Due In Rolling Year Two LoanAgreementFutureMinimumPaymentsDueInRollingYearTwo	390000	USD
CY2013Q1	nvax	Loan Agreement Future Minimum Payments Remainder Of Fiscal Year LoanAgreementFutureMinimumPaymentsRemainderOfFiscalYear	293000	USD
CY2013Q1	nvax	Number Of Auction Rate Securities Included In Investments NumberOfAuctionRateSecuritiesIncludedInInvestments	1	pure
CY2013Q1	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled	376000	USD
CY2012Q1	nvax	Reclassification From Accounts Payable To Lease Incentives Received ReclassificationFromAccountsPayableToLeaseIncentivesReceived	600000	USD
CY2012Q1	nvax	Reclassification From General Administrative Expenses To Research Development Expenses ReclassificationFromGeneralAdministrativeExpensesToResearchDevelopmentExpenses	300000	USD
CY2012Q1	nvax	Proceeds From Issuance Or Sale Of Equity Not Settled ProceedsFromIssuanceOrSaleOfEquityNotSettled		USD
CY2013Q1	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	392000	USD
CY2012Q1	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration		USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	483000	USD
CY2011Q4	nvax	Tenant Improvement Allowance TenantImprovementAllowance	2500000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2173000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3228000	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2602000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1011000	USD
CY2013Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-94000	USD
CY2012Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments		USD
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5842000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7275000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	469000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	430000	USD
CY2013Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	446191000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	438939000	USD
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	587000	USD
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15722925	shares
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14383567	shares
CY2013Q1	us-gaap	Assets Assets	98704000	USD
CY2012Q4	us-gaap	Assets Assets	102345000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	51722000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	50408000	USD
CY2013Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	35904000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	32515000	USD
CY2013Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	35256000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	26712000	USD
CY2013Q1	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	36373000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	32945000	USD
CY2013Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	469000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	430000	USD
CY2013Q1	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1		USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1		USD
CY2013Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	1117000	USD
CY2012Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	6233000	USD
CY2013Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	422000	USD
CY2012Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	224000	USD
CY2013Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	59000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	58000	USD
CY2013Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	222000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	237000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9023000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17399000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14104000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13873000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8376000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-231000	USD
CY2008Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	3.62
CY2008Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3343325	shares
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	151700247	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148398747	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	151244817	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	147943317	shares
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	1517000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	1484000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9957000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7192000	USD
CY2013Q1	us-gaap	Contract Revenue Cost ContractRevenueCost	1712000	USD
CY2012Q1	us-gaap	Contract Revenue Cost ContractRevenueCost	3786000	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	3441000	USD
CY2012Q1	us-gaap	Contracts Revenue ContractsRevenue	4642000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	13838000	USD
CY2012Q1	us-gaap	Costs And Expenses CostsAndExpenses	12109000	USD
CY2012Q3	us-gaap	Debt Instrument Basis Spread On Variable Rate DebtInstrumentBasisSpreadOnVariableRate	0.1168	pure
CY2012Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2000000	USD
CY2013Q1	us-gaap	Debt Instrument Increase Additional Borrowings DebtInstrumentIncreaseAdditionalBorrowings	800000	USD
CY2012Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage Rate Range Minimum DebtInstrumentInterestRateStatedPercentageRateRangeMinimum	0.121	pure
CY2013Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.121	pure
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2013Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	19426	USD
CY2013Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	444000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	432000	USD
CY2013Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7871000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6940000	USD
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	78000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	258000	USD
CY2013Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	449000	USD
CY2012Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	404000	USD
CY2013Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	267000	USD
CY2012Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	267000	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5100000	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y8M12D
CY2008Q3	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	2.68
CY2013Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax		USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2985000	USD
CY2013Q1	us-gaap	Goodwill Goodwill	33141000	USD
CY2012Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	101000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	17000	USD
CY2012Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2694000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	33141000	USD
CY2011Q1	us-gaap	Government Contract Receivable GovernmentContractReceivable	179000000	USD
CY2013Q1	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1571000	USD
CY2012Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	1570000	USD
CY2013Q1	us-gaap	Investment Income Net InvestmentIncomeNet	48000	USD
CY2012Q1	us-gaap	Investment Income Net InvestmentIncomeNet	33000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-9979000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7336000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17000	USD
CY2012Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1590000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-517000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1591000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-240000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-180000	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		USD
CY2013Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	703000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1557000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-54000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-183000	USD
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-769000	USD
CY2012Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
CY2013Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1000	USD
CY2012Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-427000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	22000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	3000	USD
CY2013Q1	us-gaap	Interest Paid InterestPaid	20000	USD
CY2012Q1	us-gaap	Interest Paid InterestPaid		USD
CY2013Q1	us-gaap	Liabilities Liabilities	21136000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	22105000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	98704000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	102345000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9253000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11675000	USD
CY2013Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	1290000	USD
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	753000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	144000	USD
CY2013Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-240000	USD
CY2012Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-336000	USD
CY2013Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	700000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	5000000	USD
CY2013Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	200000	USD
CY2013Q1	us-gaap	Nature Of Operations NatureOfOperations	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> Note 1 - Organization</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Novavax, Inc. (the "Company") is a clinical-stage biopharmaceutical company focused on developing recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ("VLPs") and recombinant protein micelle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target seasonal influenza, pandemic (H5N1) influenza and respiratory syncytial virus ("RSV").</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In 2009, the Company formed a joint venture with Cadila Pharmaceuticals Limited ("Cadila") named CPL Biologicals Private Limited (the "JV") to develop and manufacture vaccines, biological therapeutics and diagnostics in India. The JV is owned 20% by the Company and 80% by Cadila. The Company accounts for its investment in the JV using the equity method. Since the carrying value of the Company's initial investment was nominal and there is no guarantee or commitment to provide future funding, the Company has not recorded any losses related to this investment.</p> <!--EndFragment--></div> </div>
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7181000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7259000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4974000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3270000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10583000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4220000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-9996000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-7336000	USD
CY2013Q1	us-gaap	Notes Payable Current NotesPayableCurrent	390000	USD
CY2012Q4	us-gaap	Notes Payable Current NotesPayableCurrent	157000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10005000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7467000	USD
CY2013Q1	us-gaap	Other Assets Current OtherAssetsCurrent	886000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	171000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	350000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	351000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	39000	USD
CY2012Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
CY2013Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8718000	USD
CY2012Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	2498000	USD
CY2013Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1542000	USD
CY2012Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	772000	USD
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	757000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	756000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-368159000	USD
CY2012Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-13000	USD
CY2013Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358163000	USD
CY2012Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-755000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5235000	USD
CY2012Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities		USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	51000	USD
CY2012Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
CY2012Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11617000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11456000	USD
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2167000	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2559000	USD
CY2013Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>Reclassifications</em></strong></p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Within the March 31, 2012 statement of operations, certain expenses relating to patent and other costs of $0.3 million have been reclassified from general and administrative expenses to research and development expenses. Also, within the March 31, 2012 statement of cash flows, additional lease incentives received of $0.6 million recorded in the change in accounts payable and accrued expenses have been reclassified and are included in the change in lease incentives received. All of these reclassifications have been made to conform to current year presentation.</p> <!--EndFragment--></div> </div>
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6425000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7923000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6400000	USD
CY2008Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	17500000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	400000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3200000	USD
CY2013Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	809000	USD
CY2012Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	100000	USD
CY2013Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-39000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	14000	USD
CY2012Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations		USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9432000	USD
CY2012Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5338000	USD
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	217000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	986000	USD
CY2013Q1	us-gaap	Revenues Revenues	3833000	USD
CY2012Q1	us-gaap	Revenues Revenues	4642000	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	483000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	587000	USD
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.00
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	33334	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	33334	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7372	pure
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8048	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.6923	pure
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7552	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0134	pure
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0154	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0062	pure
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0082	pure
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1900000	USD
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.71
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6600000	USD
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	77568000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	80240000	USD
CY2013Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3300000	shares
CY2008Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6686650	shares
CY2013Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	200000	shares
CY2013Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1300000	shares
CY2013Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2013Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2013Q1	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>Use of Estimates</em></strong></p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.</p> <!--EndFragment--></div> </div>
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	148448	shares
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	120558	shares

Files In Submission

Name	View Source	Status
0001144204-13-027413-index-headers.html	Edgar Link	pending
0001144204-13-027413-index.html	Edgar Link	pending
0001144204-13-027413.txt	Edgar Link	pending
0001144204-13-027413-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nvax-20130331.xml	Edgar Link	completed
nvax-20130331.xsd	Edgar Link	pending
nvax-20130331_cal.xml	Edgar Link	unprocessable
nvax-20130331_def.xml	Edgar Link	unprocessable
nvax-20130331_lab.xml	Edgar Link	unprocessable
nvax-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v342987_10q.htm	Edgar Link	pending
v342987_ex31-1.htm	Edgar Link	pending
v342987_ex31-2.htm	Edgar Link	pending
v342987_ex32-1.htm	Edgar Link	pending
v342987_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2013 Q2 Form 10-Q Financial Statement

#000114420413027413 Filed on May 09, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2013 Q2 Form 10-Q Financial Statement

#000114420413027413 Filed on May 09, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax